IL ‐6/STAT3 promotes prostate cancer resistance to androgen deprivation therapy via regulating PTTG1 expression

In conclusion, our results elucidate that IL‐6/STAT3 activation can increase PTTG1 expression and consequently promote the resistance to ADT in CRPC via inducing EMT and increasing the cancer stem cell population, suggesting that PTTG1 may be a novel therapeutic target for CRPC.
This article is protected by copyright. All rights reserved.

Source: Cancer Science - December 30, 2017 Category: Cancer & Oncology Authors: Shengquan Huang, Qian Liu, Qianjin Liao, Qingjian Wu, Bishao Sun, Zhenxing Yang, Xiaoyan Hu, Mingjia Tan, Longkun Li Tags: Original Article Source Type: research